Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report

Buti, Sebastiano; Riccò, Matteo; Chiesa, Matteo Dalla; Copercini, B.; Tomasello, Gianluca; Brighenti, Matteo; Passalacqua, Rodolfo

doi:10.1097/cad.0b013e3280102f4b

Cited by 29 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, trisomies resulted from robertsonian translocations are extremely rare [8]. In the literature there is only one CML patient diagnosed in blastic phase carrying both Ph chromosome and translocation (14;14) who has a similar disease progress as in our case [9].…”

Section: To the Editormentioning

confidence: 67%

Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: A case report

et al. 2008

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 67%

Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: A case report

et al. 2008

View full text Add to dashboard Cite

“…Lee et al [5] reported that the important grade 3-4 toxicities were neutropenia (34.1 %), leukopenia (7.3 %), nausea (9.8 %), and vomiting (7.3 %). Hemolysis and renal toxicity related to oxaliplatin are quite rare, reported in only a few cases [6][7][8][9][10][11][12]. Cases with acute renal injury have been reported in only seven patients to date.…”

Section: Introductionmentioning

confidence: 92%

A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin

Ito

Mizuno

et al. 2012

Clin Exp Nephrol

View full text Add to dashboard Cite

Oxaliplatin is effective in advanced colorectal cancer and is known to have relatively few side effects, such as hemolysis and renal toxicity. We report a case of acute kidney injury (AKI) after treatment with a combination of oxaliplatin, folinic acid and 5-fluorouracil or capecitabine. The patient developed acute renal failure, hemolytic anemia and thrombocytopenia after the 34th course of chemotherapy including oxaliplatin. A positive direct antiglobulin test and detection of immunoglobulin G and complement C3b and C3d on erythrocytes suggested the diagnosis of immune-related severe intravascular hemolytic anemia. She was successfully treated and recovered using plasma exchange, corticosteroids and hemodialysis therapy. Only seven other cases of AKI associated with oxaliplatin use have been reported to date. As in this case, acute hemolysis due to autoimmune mechanisms and subsequent AKI occurred suddenly after frequent use of oxaliplatin in four of those cases. We should be aware that oxaliplatin may cause sudden life-threatening hemolysis by drug-induced antibodies and subsequent AKI, even though oxaliplatin is frequently administered without side effects. This represents the first case report of AKI-related hemolysis due to oxaliplatin in Japan.

show abstract

“…It was not possible to study all the components of the disease, so in this case we considered cancer a major risk factor and CHT as the main and most probable cause of presented symptoms and signs. There are multiple reports in the literature about haematologic complications in cancer patients (21)(22)(23)(24)(25)(26). Here we concluded that HUS/TTP and Evans syndrome are the most probable CHTinduced diseases.…”

Section: Resultsmentioning

confidence: 75%

“…The intervention of plasma-exchange is ineffective in HUS because its role is antibodies removal and Von Willebrand Factor-cleaving protease replacement. HUS is more common in children and is subdivided into typical HUS, which is associated with intestinal infection with Shiga-toxin producing bacteria or atypical HUS, which is not related to a specifi c infection and may also be caused by certain drugs (26).…”

Section: Discussionmentioning

confidence: 99%

Oxaliplatin-Induced Haemolytic Anaemia: A Case Report

Compostella

Ghiotto

et al. 2007

Clinical medicine. Oncology

View full text Add to dashboard Cite

Oxaliplatin plus 5Fluorouracil (5FU) and leucovorin (LV) is the standard treatment of metastatic colorectal cancer (CRC). We describe a rare clinical case of acute renal failure probably oxaliplatin-related at one day from the end of the palliative treatment. A 36 year-old woman developed a stage I CRC. Five months later a liver lesion was detected and treated with FOLFOX4 schedule. Because of progression the patient underwent surgery and she repeated the Oxaliplatin-based therapy for more than one cycle. After many months of therapy, on the second day, the patient noticed urine discoloration. Immediate urinanalysis demonstrated haemoglobinuria. The patient's complete blood count exhibited signs consistent with acute hemolysis, neutrophilic leucocytosis, thrombocytopenia and acute renal failure. She was treated with blood transfusion and hemodialysis and she was managed conservatively with monitored intravenous hydration and loop diuretics. The patient gradually recovered and the results of successive hematological and biochemical tests confi rmed the improvement of her condition but a cardiologic evaluation showed a iatrogenic depressed systolic function (ejection fraction of 40%).

show abstract

Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report

Cited by 29 publications

References 23 publications

Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: A case report

Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: A case report

A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin

Oxaliplatin-Induced Haemolytic Anaemia: A Case Report

Contact Info

Product

Resources

About